search
Back to results

Danhong Injection in the Treatment of Acute Ischemic Stroke

Primary Purpose

Acute Stroke

Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Danhong injection
Standard medical care
placebo
Sponsored by
China Academy of Chinese Medical Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Acute Stroke focused on measuring Acute Ischemic Stroke, Randomized Controlled Trial, Traditional Chinese Medicine

Eligibility Criteria

18 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Female or male inpatients
  • Age: 18 - 70 years.
  • Clinical diagnosis of ischemic stroke causing a measurable neurological deficit defined as impairment of language, motor function, cognition and/or gaze, vision or neglect. Ischemic stroke is defined as an event characterized by the sudden onset of an acute focal neurologic deficit presumed to be due to cerebral ischemia after CT scan excludes hemorrhage.
  • Clinical diagnosis of "Xueyu Zheng" (Blood Stasis Syndrome) as the scores of Chinese medicine symptoms scales of "Xueyu Zheng" in ischemic stroke ≥ 20. The Chinese medicine symptoms scales of "Xueyu Zheng" is defined as following (1)hemiplegia-10,(2)numbness of limbs-10，(3) dark face-9,(4)purple or dark lip-8,(5)Roughness of skin-4, (6) pain with fixed point-5, (7) purple or dark tongue-10,(8)ecchymosis on tongue-10,(9)purple sublingual vessel-10,(10)varicose sublingual vessel-8,(11)unsmooth pulse-8,(12)intermittent pulse-1.
  • Onset of symptoms in 1 week prior to initiation of administration of study drug.
  • Clinical diagnosis of cerebral anterior circulation obstruction.
  • 4≤NIHSS<20.
  • Patient is willing to participate voluntarily and to sign a written patient informed consent. Informed consent will be obtained from each patient or the subject's legally authorized representative or relatives, or deferred where applicable, according to the regulatory and legal requirements of the participating centers.

Exclusion Criteria:

  • Evidence of intracranial hemorrhage (ICH) or other cerebral diseases (eg.vascular malformation, tumor, abscess or multiple sclerosis etc.)on the CT-or MRI-scan.
  • Patients with thrombolysis or endovascular treatment.
  • Known history of allergy or suspected allergic to the drug.
  • Blood glucose 2.8 or > 16.8 mmol / l under the treatment of diabetes or with severe complications due to diabetes (eg. peripheral neuropathy, diabetic gangrene).
  • Liver function impairment with the value of ALT or AST over 1.5-fold of normal value.
  • Renal dysfunction with the value of serum creatinine over 1.5-fold of normal value.
  • Severe cardiac dysfunction on echocardiogram or the grade of heart function over Ⅲ grade.
  • History of prior stroke with mRS ≥2.
  • Complicated with atrial fibrillation.
  • Severe stroke as assessed by appropriate imaging techniques (eg. massive cerebral infarction including more than one lobe of brain or over 1/3 of blood-supply area of middle cerebral artery).
  • Prior disable patients.
  • Hemorrhagic tendency or recent severe or dangerous bleeding in 3 months.
  • Suspected addicted into alcohol or drug abuse.
  • With severe complications that would make the condition more complicated assessed by the investigator.
  • Woman with pregnancy, lactation or positive result of pregnancy test, or women who want to be pregnant in recent 6 months.
  • Woman who is under menstrual period.
  • Patient who is participating in other trials or has been participated in other trials in recent 3 months.

Sites / Locations

  • The Second Artillery General Hospital of Chinese People's Liberation Army
  • Xinqiao Hospital of Third Military Medical University
  • Chongqing Three Gorges Central Hospital
  • Guangdong No.2 Provincial People's Hospital
  • Guangzhou hospital of integrated Chinese and Western medicine
  • The Second People's Hospital of Shenzhen
  • The Second Central Hospital of Baoding City
  • Affiliated Hospital of Chengde Medical University
  • Handan Central Hospital
  • The Second Affiliated Hopital of Harbin Medical University
  • The Second Chinese Medical Hospital of Luoyang City
  • Nanyang T.C.M. Hospital
  • Nanshi Hospital of Nanyang
  • The First Affiliated Hospital of Henan University of T.C.M.
  • People's Hospital of Zhengzhou
  • Zhengzhou NO.7 People's Hospital
  • Zhoukou Hospital of T.C.M.
  • The Central Hospital of Wuhan
  • Zhongnan Hospital of Wuhan University
  • Zhongshan Hospital of Hubei Province
  • Fifth Hospital in Wuhan
  • Renmin Hospital of Wuhan University
  • Tianyou Hospital Affiliated to Wuhan University of Science & Technology
  • Huangpi District Hospital of T.C.M.
  • Changsha Central Hospital
  • The First Hospital of Changsha
  • The second people's hospital of Hunan Province
  • Xiangya Hospital Central-south University
  • Nanjing Hospital of T.C.M.
  • The Second Affiliated Hospital of Nanjing Medical University
  • Nanjing Drum Tower Hospital
  • Jilin Province People's Hospital
  • The Affiliated Hopital to Changchun University of Chinese Medicine
  • The First Hospital Affiliated to Jilin University
  • China-Japan Union Hospital of Jilin University
  • The Second Hospital of Jilin University
  • Liaoyuan Traditional Chinese Medical Hospital
  • Anshan Central Hospital
  • Affiliated Zhongshan Hospital of Dalian University
  • Dandong First Hospital
  • Panjin Central Hospital
  • People's Liberation Army No.202 Hospital
  • The General Hospital of Shenyang Military
  • People's Liberation Army No.463 Hospital
  • Affiliated Hospital of Chifeng University
  • Fenyang Hospital of Shanxi Province
  • The Second Affiliated Hospital to Shanxi Medical University
  • Shanxi Province Hospital of T.C.M.
  • The PLA Fourth Fifty-one Hospital
  • Shanxi Provincial People's Hospital
  • Affiliated Hospital of Shanxi University of Chinese Medicine
  • The Second Affiliated Hospital of Shanxi University of T.C.M.
  • Teaching Hospital of Chengdu University of Traditional Chinese Medicine
  • The First Affiliated Hopital of Chengdu Medical College
  • First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
  • Xin Hua Hospital of Zhejiang Province
  • Zhejiang Provincial Hospital of T.C.M.
  • Zhejiang Provincial People's Hospital
  • Huzhou Central Hospital
  • Peking University First Hospital
  • Tiantan Hospital Affiliated to Capital Medical University
  • Xuan Wu Hospital Affiliated to Capital Medical University

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Danhong injection

placebo

Arm Description

Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.

Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.

Outcomes

Primary Outcome Measures

Modified Rankin Scale 0-1 (favourable outcome) at Day 90

Secondary Outcome Measures

The Score of effect on symptoms of "Xueyue Zheng"(Blood Stasis syndrome)
Barthel Index score ≥90
NIH stroke scale(NIHSS)
The improvement of the NIHSS score ≥4 or the NIHSS score of 0 to 1
EQ-5D scale
Global disability on mRS at Day 90.
The proportion of patients with mRS ≥3 at Day 90.
Incidence of new-onset major vascular events in 90 days
Major adverse vascular events include ischemic stroke, hemorrhagic stroke, TIA, myocardial infarction and vascular-related death.
Overall mortality at day 90
Incidence of severe hemorrhages in 90 days
The definition of "Severe hemorrhages" is in accordance with the GUSTO bleeding criteria, including fatal intracranial hemorrhage (ICH), symptomatic intracerebral hemorrhage (sICH) or which could result in substantial hemodynamic compromise requiring treatment.
Incidence of moderate hemorrhages in 90 days
The definition of "moderate hemorrhages" is in accordance with the GUSTO bleeding criteria, which requires blood transfusion but not results in hemodynamic compromise.
Documentation of adverse events (AEs) and serious AEs

Full Information

First Posted
August 29, 2012
Last Updated
June 6, 2022
Sponsor
China Academy of Chinese Medical Sciences
Collaborators
China Food and Drug Administration
search

1. Study Identification

Unique Protocol Identification Number
NCT01677208
Brief Title
Danhong Injection in the Treatment of Acute Ischemic Stroke
Official Title
A Randomized, Multi-center, Double-blind, Placebo-controlled Trial of Danhong Injection in the Treatment of Acute Ischemic Stroke
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Completed
Study Start Date
March 13, 2013 (Actual)
Primary Completion Date
March 10, 2019 (Actual)
Study Completion Date
March 27, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
China Academy of Chinese Medical Sciences
Collaborators
China Food and Drug Administration

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this study is to determine whether Danhong injection is effective in the treatment of acute ischemic stroke.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Stroke
Keywords
Acute Ischemic Stroke, Randomized Controlled Trial, Traditional Chinese Medicine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
1503 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Danhong injection
Arm Type
Experimental
Arm Description
Based on the standard medical care, 40ml of Danhong injection, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
Arm Title
placebo
Arm Type
Placebo Comparator
Arm Description
Based on the standard medical care, 40ml of 0.9% saline as the placebo, added into 250ml of 0.9% saline, given by continuous IV infusion at 2.5ml/min within 2 hours.
Intervention Type
Drug
Intervention Name(s)
Danhong injection
Intervention Description
A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
Intervention Type
Procedure
Intervention Name(s)
Standard medical care
Intervention Description
Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
Intervention Type
Drug
Intervention Name(s)
placebo
Intervention Description
0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
Primary Outcome Measure Information:
Title
Modified Rankin Scale 0-1 (favourable outcome) at Day 90
Time Frame
Day 90
Secondary Outcome Measure Information:
Title
The Score of effect on symptoms of "Xueyue Zheng"(Blood Stasis syndrome)
Time Frame
Day 0, Day7, Day 14, Day 30, Day 60, Day 90
Title
Barthel Index score ≥90
Time Frame
Day 0, Day7, Day 14, Day 30, Day 60, Day 90
Title
NIH stroke scale(NIHSS)
Description
The improvement of the NIHSS score ≥4 or the NIHSS score of 0 to 1
Time Frame
Day 0, Day7, Day 14, Day 30, Day 60, Day 90
Title
EQ-5D scale
Time Frame
Day 0, Day 7, Day 14, Day 30, Day 60, Day 90
Title
Global disability on mRS at Day 90.
Description
The proportion of patients with mRS ≥3 at Day 90.
Time Frame
Day 90
Title
Incidence of new-onset major vascular events in 90 days
Description
Major adverse vascular events include ischemic stroke, hemorrhagic stroke, TIA, myocardial infarction and vascular-related death.
Time Frame
Day 90
Title
Overall mortality at day 90
Time Frame
Day 90
Title
Incidence of severe hemorrhages in 90 days
Description
The definition of "Severe hemorrhages" is in accordance with the GUSTO bleeding criteria, including fatal intracranial hemorrhage (ICH), symptomatic intracerebral hemorrhage (sICH) or which could result in substantial hemodynamic compromise requiring treatment.
Time Frame
Day 90
Title
Incidence of moderate hemorrhages in 90 days
Description
The definition of "moderate hemorrhages" is in accordance with the GUSTO bleeding criteria, which requires blood transfusion but not results in hemodynamic compromise.
Time Frame
Day 90
Title
Documentation of adverse events (AEs) and serious AEs
Time Frame
90 days
Other Pre-specified Outcome Measures:
Title
The changes on the profiles of micro-RNA in 96 patients selected from certain centers
Time Frame
Day 0, Day 14, Day 90
Title
The changes on the expression profiles of mRNA in 96 patients selected from certain centers
Time Frame
Day 0, Day 14, Day 90

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Female or male inpatients Age: 18 - 70 years. Clinical diagnosis of ischemic stroke causing a measurable neurological deficit defined as impairment of language, motor function, cognition and/or gaze, vision or neglect. Ischemic stroke is defined as an event characterized by the sudden onset of an acute focal neurologic deficit presumed to be due to cerebral ischemia after CT scan excludes hemorrhage. Clinical diagnosis of "Xueyu Zheng" (Blood Stasis Syndrome) as the scores of Chinese medicine symptoms scales of "Xueyu Zheng" in ischemic stroke ≥ 20. The Chinese medicine symptoms scales of "Xueyu Zheng" is defined as following (1)hemiplegia-10,(2)numbness of limbs-10，(3) dark face-9,(4)purple or dark lip-8,(5)Roughness of skin-4, (6) pain with fixed point-5, (7) purple or dark tongue-10,(8)ecchymosis on tongue-10,(9)purple sublingual vessel-10,(10)varicose sublingual vessel-8,(11)unsmooth pulse-8,(12)intermittent pulse-1. Onset of symptoms in 1 week prior to initiation of administration of study drug. Clinical diagnosis of cerebral anterior circulation obstruction. 4≤NIHSS<20. Patient is willing to participate voluntarily and to sign a written patient informed consent. Informed consent will be obtained from each patient or the subject's legally authorized representative or relatives, or deferred where applicable, according to the regulatory and legal requirements of the participating centers. Exclusion Criteria: Evidence of intracranial hemorrhage (ICH) or other cerebral diseases (eg.vascular malformation, tumor, abscess or multiple sclerosis etc.)on the CT-or MRI-scan. Patients with thrombolysis or endovascular treatment. Known history of allergy or suspected allergic to the drug. Blood glucose 2.8 or > 16.8 mmol / l under the treatment of diabetes or with severe complications due to diabetes (eg. peripheral neuropathy, diabetic gangrene). Liver function impairment with the value of ALT or AST over 1.5-fold of normal value. Renal dysfunction with the value of serum creatinine over 1.5-fold of normal value. Severe cardiac dysfunction on echocardiogram or the grade of heart function over Ⅲ grade. History of prior stroke with mRS ≥2. Complicated with atrial fibrillation. Severe stroke as assessed by appropriate imaging techniques (eg. massive cerebral infarction including more than one lobe of brain or over 1/3 of blood-supply area of middle cerebral artery). Prior disable patients. Hemorrhagic tendency or recent severe or dangerous bleeding in 3 months. Suspected addicted into alcohol or drug abuse. With severe complications that would make the condition more complicated assessed by the investigator. Woman with pregnancy, lactation or positive result of pregnancy test, or women who want to be pregnant in recent 6 months. Woman who is under menstrual period. Patient who is participating in other trials or has been participated in other trials in recent 3 months.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhong Wang, Professor
Organizational Affiliation
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Xing-quan Zhao, Professor
Organizational Affiliation
Beijing Tiantan Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Yong-yan Wang, Professor
Organizational Affiliation
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Xiao-xi Du, Professor
Organizational Affiliation
China Food and Drug Administration
Official's Role
Study Director
Facility Information:
Facility Name
The Second Artillery General Hospital of Chinese People's Liberation Army
City
Beijing
State/Province
Beijing
ZIP/Postal Code
100088
Country
China
Facility Name
Xinqiao Hospital of Third Military Medical University
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
400037
Country
China
Facility Name
Chongqing Three Gorges Central Hospital
City
Chongqing
State/Province
Chongqing
ZIP/Postal Code
404000
Country
China
Facility Name
Guangdong No.2 Provincial People's Hospital
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510317
Country
China
Facility Name
Guangzhou hospital of integrated Chinese and Western medicine
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510813
Country
China
Facility Name
The Second People's Hospital of Shenzhen
City
Shenzhen
State/Province
Guangdong
ZIP/Postal Code
518028
Country
China
Facility Name
The Second Central Hospital of Baoding City
City
Baoding
State/Province
Hebei
ZIP/Postal Code
072750
Country
China
Facility Name
Affiliated Hospital of Chengde Medical University
City
Chengde
State/Province
Hebei
ZIP/Postal Code
067000
Country
China
Facility Name
Handan Central Hospital
City
Handan
State/Province
Hebei
ZIP/Postal Code
056001
Country
China
Facility Name
The Second Affiliated Hopital of Harbin Medical University
City
Harbin
State/Province
Helongjiang
ZIP/Postal Code
150001
Country
China
Facility Name
The Second Chinese Medical Hospital of Luoyang City
City
Luoyang
State/Province
Henan
ZIP/Postal Code
471003
Country
China
Facility Name
Nanyang T.C.M. Hospital
City
Nanyang
State/Province
Henan
ZIP/Postal Code
473007
Country
China
Facility Name
Nanshi Hospital of Nanyang
City
Nanyang
State/Province
Henan
ZIP/Postal Code
473065
Country
China
Facility Name
The First Affiliated Hospital of Henan University of T.C.M.
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450000
Country
China
Facility Name
People's Hospital of Zhengzhou
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450003
Country
China
Facility Name
Zhengzhou NO.7 People's Hospital
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450006
Country
China
Facility Name
Zhoukou Hospital of T.C.M.
City
Zhoukou
State/Province
Henan
ZIP/Postal Code
466099
Country
China
Facility Name
The Central Hospital of Wuhan
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430014
Country
China
Facility Name
Zhongnan Hospital of Wuhan University
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430030
Country
China
Facility Name
Zhongshan Hospital of Hubei Province
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430033
Country
China
Facility Name
Fifth Hospital in Wuhan
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430050
Country
China
Facility Name
Renmin Hospital of Wuhan University
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430060
Country
China
Facility Name
Tianyou Hospital Affiliated to Wuhan University of Science & Technology
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430064
Country
China
Facility Name
Huangpi District Hospital of T.C.M.
City
Wuhan
State/Province
Hubei
ZIP/Postal Code
430399
Country
China
Facility Name
Changsha Central Hospital
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410004
Country
China
Facility Name
The First Hospital of Changsha
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410005
Country
China
Facility Name
The second people's hospital of Hunan Province
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410007
Country
China
Facility Name
Xiangya Hospital Central-south University
City
Changsha
State/Province
Hunan
ZIP/Postal Code
410008
Country
China
Facility Name
Nanjing Hospital of T.C.M.
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210001
Country
China
Facility Name
The Second Affiliated Hospital of Nanjing Medical University
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210003
Country
China
Facility Name
Nanjing Drum Tower Hospital
City
Nanjing
State/Province
Jiangsu
ZIP/Postal Code
210008
Country
China
Facility Name
Jilin Province People's Hospital
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130021
Country
China
Facility Name
The Affiliated Hopital to Changchun University of Chinese Medicine
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130021
Country
China
Facility Name
The First Hospital Affiliated to Jilin University
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130021
Country
China
Facility Name
China-Japan Union Hospital of Jilin University
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130033
Country
China
Facility Name
The Second Hospital of Jilin University
City
Changchun
State/Province
Jilin
ZIP/Postal Code
130041
Country
China
Facility Name
Liaoyuan Traditional Chinese Medical Hospital
City
Liaoyuan
State/Province
Jilin
ZIP/Postal Code
136299
Country
China
Facility Name
Anshan Central Hospital
City
Anshan
State/Province
Liaoning
ZIP/Postal Code
114001
Country
China
Facility Name
Affiliated Zhongshan Hospital of Dalian University
City
Dalian
State/Province
Liaoning
ZIP/Postal Code
116001
Country
China
Facility Name
Dandong First Hospital
City
Dandong
State/Province
Liaoning
ZIP/Postal Code
118015
Country
China
Facility Name
Panjin Central Hospital
City
Panjin
State/Province
Liaoning
ZIP/Postal Code
124013
Country
China
Facility Name
People's Liberation Army No.202 Hospital
City
Shenyang
State/Province
Liaoning
ZIP/Postal Code
110003
Country
China
Facility Name
The General Hospital of Shenyang Military
City
Shenyang
State/Province
Liaoning
ZIP/Postal Code
110016
Country
China
Facility Name
People's Liberation Army No.463 Hospital
City
Shenyang
State/Province
Liaoning
ZIP/Postal Code
110046
Country
China
Facility Name
Affiliated Hospital of Chifeng University
City
Chifeng
State/Province
Neimenggu
ZIP/Postal Code
024005
Country
China
Facility Name
Fenyang Hospital of Shanxi Province
City
Luliang
State/Province
Shanxi
ZIP/Postal Code
032299
Country
China
Facility Name
The Second Affiliated Hospital to Shanxi Medical University
City
Taiyuan
State/Province
Shanxi
ZIP/Postal Code
030001
Country
China
Facility Name
Shanxi Province Hospital of T.C.M.
City
Xi'an
State/Province
Shanxi
ZIP/Postal Code
710003
Country
China
Facility Name
The PLA Fourth Fifty-one Hospital
City
Xi'an
State/Province
Shanxi
ZIP/Postal Code
710054
Country
China
Facility Name
Shanxi Provincial People's Hospital
City
Xi'an
State/Province
Shanxi
ZIP/Postal Code
710068
Country
China
Facility Name
Affiliated Hospital of Shanxi University of Chinese Medicine
City
Xianyang
State/Province
Shanxi
ZIP/Postal Code
712000
Country
China
Facility Name
The Second Affiliated Hospital of Shanxi University of T.C.M.
City
Xianyang
State/Province
Shanxi
ZIP/Postal Code
712000
Country
China
Facility Name
Teaching Hospital of Chengdu University of Traditional Chinese Medicine
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610072
Country
China
Facility Name
The First Affiliated Hopital of Chengdu Medical College
City
Chengdu
State/Province
Sichuan
ZIP/Postal Code
610500
Country
China
Facility Name
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
City
Tianjin
State/Province
Tianjin
ZIP/Postal Code
300193
Country
China
Facility Name
Xin Hua Hospital of Zhejiang Province
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310005
Country
China
Facility Name
Zhejiang Provincial Hospital of T.C.M.
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310006
Country
China
Facility Name
Zhejiang Provincial People's Hospital
City
Hangzhou
State/Province
Zhejiang
ZIP/Postal Code
310014
Country
China
Facility Name
Huzhou Central Hospital
City
Huzhou
State/Province
Zhejiang
ZIP/Postal Code
313003
Country
China
Facility Name
Peking University First Hospital
City
Beijing
ZIP/Postal Code
100034
Country
China
Facility Name
Tiantan Hospital Affiliated to Capital Medical University
City
Beijing
ZIP/Postal Code
100050
Country
China
Facility Name
Xuan Wu Hospital Affiliated to Capital Medical University
City
Beijing
ZIP/Postal Code
100053
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
26654631
Citation
Li B, Wang Y, Lu J, Liu J, Yuan Y, Yu Y, Wang P, Zhao X, Wang Z. Evaluating the effects of Danhong injection in treatment of acute ischemic stroke: study protocol for a multicenter randomized controlled trial. Trials. 2015 Dec 9;16:561. doi: 10.1186/s13063-015-1076-4.
Results Reference
derived

Learn more about this trial

Danhong Injection in the Treatment of Acute Ischemic Stroke

We'll reach out to this number within 24 hrs